





Functional impairment is a major concern in the obese 
population, leading to reductions in everyday activities 
[1]. Obesity-related reductions in muscle function are 
due to a loss of muscle mass (i.e. sarcopenia), which 
occurs largely from an imbalance between the rates of 
protein synthesis and degradation [2,3]. A major 
controlling mechanism for muscle peptide/protein 
formation is messenger RNA (mRNA) translation. 
Initiation of translation is regulated by hormones and 
the diet through alterations in the mammalian Target of 
Rapamycin (mTOR) [4,5,6]. Despite hyperactivation of 
the growth-promoting, nutrient-sensing mTOR 
pathway, atrophy persists in obese muscle [7]. Chronic 
hyperactivation of mTOR signaling is atypical outside 
of disease states, such as obesity, dyslipidemia, 
hypercholesterolemia, or certain types of cancer. With 
the obesity rate growing at an alarming rate, there is a 
critical need to determine how obesity-related 
sarcopenia can be limited, since metabolic homeostasis 
is positively linked to muscle mass. 
 
Given the hyperactive state of mTOR signaling in obese 
skeletal muscle, normalizing mTOR signaling (to levels 
observed in lean mice) may be one avenue of limiting 
the resultant sarcopenia. However, treatment of obese 
rodent models with the mTOR inhibitor, rapamycin, 
showed limited improvement in insulin sensitivity, 
despite reductions in adiposity [8]. Although, recent 
studies show that aged [9] and cancer prone [10] mice 
can withstand chronic rapamycin treatment. This 
suggests that the efficacy of chronic rapamycin 
treatment may rely upon the dose, delivery method, 
tissue-specific effects, and length of treatment. This 
issue requires more work.   Likewise,  the use of  insulin 
 
 



















sensitizers and/or AMP-activated protein kinase 
(AMPK)-agonists [11] has proven beneficial in 
improving obesity-related metabolic complications in 
skeletal muscle. AMPK is a well-characterized sensor 
of the cell’s energy status [12]. Compounds like AICAR 
(an AMP mimetic) and metformin, lead to the activation 
and phosphorylation of AMPK. AMPK activation 
promotes enhanced expression of skeletal muscle 
oxidative-related enzymes, proteins, and metabolism, 
which are consistent with the findings that obese 
skeletal muscles are less oxidative and have lower 
AMPK activation (during fasted conditions).  At the 
same time, AMPK activation also inhibits mTOR 
signaling [13,14].  However, it seems counterintuitive to 
inhibit an important growth-mediated pathway (i.e. 
mTOR), regulating muscle mass, so that skeletal 
muscles can grow. 
 
Our recent data [15] show that short-term (2-week), 
daily treatment of obese (ob/ob) mice with AICAR 
normalized their hyperactive, fasted-state mTOR 
signaling. Along with the expected reductions in 
circulating blood glucose and insulin concentrations, 
and muscle lipid and glycogen content after AICAR 
treatment, translational capacity and mass (including 
muscle fiber areas) of the plantar flexor muscle complex 
were significantly increased in the obese treated mice. It 
is our view that the oxidative metabolism/capacity of 
the muscle and the regulatory processes of muscle 
growth (i.e. mTOR and translational control) need to be 
normalized to elicit growth in insulin resistant (e.g. 
obese, aged) muscle. There are emerging data 
[16,17,18,19,20] that support our contention. Thus, 
gaining control of these initial signals and processes in 
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